• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Cardiovascular diseases — Promoting self-healing after heart attack

Bioengineer by Bioengineer
June 11, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Myocardial infarction (MI) results in the localized death of the muscle cells that are essential for the heart’s pumping function. Depending on the extent of the damage, MI may initiate a progressive deterioration of cardiac function that ultimately leads to heart failure. Following an acute infarction, cells of the immune system induce an inflammatory reaction in the heart muscle, which promotes clearance of the damaged tissue. “Many novel post-infarct therapies are designed to inhibit the inflammation,” says Professor Oliver Söhnlein of the Institute for Cardiovascular Prevention at LMU. “However, inflammatory reactions everywhere in the body are normally self-limiting. So we set out to develop a therapeutic approach which makes use of the endogenous processes that enable the inflammation to be turned off,” he explains. A new study, which appears in the Journal of the American College of Cardiology, reports how much progress Söhnlein and his team have made so far.

At the core of their strategy is the protein annexin A1 (AnxA1), which plays an important role in the regulation of the innate immune response – in particular in the switch from the damage-disposal phase of inflammation to the restorative processes that lead to its resolution and healing. In the new study, the authors used two strains of mice. One lacked the ability to synthesize AnxA1, while the other served as the positive control. In mice that were unable to produce AnxA1, the inflammatory reaction induced by MI was more widespread and persistent, and the degree of impairment of cardiac function was greater, than in the control mice. Furthermore, therapeutic administration of AnxA1 following heart damage was found to promote myocardial repair in wild type mice.

The protein causes immune cells called macrophages to secrete the signal protein VEGF-A, which stimulates the formation of new blood vessels. “This in turn helps to increase blood flow, which is a crucial factor in the healing process after myocardial infarction,” says Söhnlein. He and his colleagues have observed similar positive effects of AnxA1 on the repair of heart damage in pigs. “So the annexin A1-based therapy looks like a promising approach to mitigating the effects of acute heart attacks.”

###

Media Contact
Dr. Kathrin Bilgeri
[email protected]
http://dx.doi.org/10.1016/j.jacc.2019.03.503

Tags: CardiologyMedicine/Health
Share13Tweet8Share2ShareShareShare2

Related Posts

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

February 7, 2026

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

February 7, 2026

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

February 7, 2026

Multidisciplinary Evidence-Based Guidelines for Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

Neg-Entropy: The Key Therapeutic Target for Chronic Diseases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.